Kelly E Dooley
Johns Hopkins University
H-index: 47
North America-United States
Top articles of Kelly E Dooley
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial | American Journal of Respiratory and Critical Care Medicine | Kamunkhwala Gausi Elisa H Ignatius Veronique De Jager Caryn Upton Soyeon Kim | 2024/4/2 |
Multidrug-resistant tuberculosis | The Lancet | José A Caminero Alberto L García-Basteiro Adrian Rendon | 2019/7/27 |
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis | Clinical Infectious Diseases | Huy X Ngo Ava Y Xu Gustavo E Velásquez Nan Zhang Vincent K Chang | 2024/3/11 |
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard-versus high-dose rifampicin | Antimicrobial Agents and Chemotherapy | Allan Kengo Ruth Nabisere Kamunkhwala Gausi Joseph Musaazi Allan Buzibye | 2023/11/15 |
Dolutegravir once daily with rifampicin for HIV and tuberculosis | The Lancet HIV | Anushka Naidoo Kelly E Dooley | 2023/7/1 |
Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with tuberculosis and human immunodeficiency virus receiving high-dose … | Clinical Infectious Diseases | Christine Sekaggya-Wiltshire Ruth Nabisere Joseph Musaazi Brian Otaalo Florence Aber | 2023/2/1 |
Sex differences in tb clinical presentation, drug exposure, and treatment outcomes in India | Chest | Sona Deshmukh Manasi Sane Sanjay Gaikwad Tushar Sahasrabudhe Madhusudan Barthwal | 2023/4/1 |
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial | EClinicalMedicine | Prasanna Jagannathan Kara W Chew Mark J Giganti Michael D Hughes Carlee Moser | 2023/11/1 |
Cerebrospinal fluid and tuberculous meningitis | Clinical Infectious Diseases | Caryn M Upton Lubbe Wiesner Kelly E Dooley Gary Maartens | 2023/7/1 |
Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model | British Journal of Clinical Pharmacology | Aida N Kawuma Roeland E Wasmann Kelly E Dooley Gary Maartens Paolo Denti | 2023/3 |
Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity | JAIDS Journal of Acquired Immune Deficiency Syndromes | Keri Geiger Amita Patil Chakra Budhathoki Kelly E Dooley Kelly Lowensen | 2023/11/1 |
A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis | Research square | Lennert Verboven Steven Callens John Black Gary Maartens Kelly E Dooley | 2023/2/16 |
A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis | Frontiers in Pharmacology | Roeland E Wasmann Tiziana Masini Kerri Viney Sabine Verkuijl Annemieke Brands | 2023 |
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection | Emmanuella Chinonso Osuala Anushka Naidoo Kelly E Dooley Kogieleum Naidoo Rubeshan Perumal | 2023/10/3 | |
Standards for clinical trials for treating TB | The International Journal of Tuberculosis and Lung Disease | P du Cros J Greig J-WC Alffenaar GB Cross C Cousins | 2023/12/1 |
High isoniazid exposures when administered with rifapentine once weekly for latent tuberculosis in individuals with human immunodeficiency virus | Antimicrobial agents and chemotherapy | Ryan T Jarrett Yuri van der Heijden Matthew S Shotwell Violet Chihota Mark A Marzinke | 2023/2/16 |
Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction | Frontiers in Chemistry | Timon Geib Cristina Lento Derek J Wilson Lekha Sleno | 2019/8/13 |
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin | Antimicrobial Agents and Chemotherapy | Allan Kengo Kamunkhwala Gausi Ruth Nabisere Joseph Musaazi Allan Buzibye | 2023/11/15 |
Clinical standards for the management of adverse effects during treatment for TB | The International Journal of Tuberculosis and Lung Disease | KP Singh ACC Carvalho R Centis GB Migliori SG Mpagama | 2023/7/1 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349) | Clinical Infectious Diseases | April C Pettit Patrick PJ Phillips Ekaterina Kurbatova Andrew Vernon Payam Nahid | 2023/2/1 |
Co-Authors
